drugset / Trial / NCT00036790

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining motexafin gadolinium with doxorubicin in treating patients who have recurrent or metastatic cancer.

Timeline

Start
2002-02
Primary completion
2005-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified Intravenous
Subject motexafin gadolinium Diagnostic / imaging agent Intravenous